Journal article

Pathophysiological mechanisms explaining poor clinical outcome of older cancer patients with low skeletal muscle mass

Stephanie MLM Looijaard, Miriam L te Lintel Hekkert, Rob C Wust, Rene HJ Otten, Carel GM Meskers, Andrea B Maier

Acta Physiologica | WILEY | Published : 2020


Low skeletal muscle mass is highly prevalent in older cancer patients and affects 5% to 89% depending on the type and stage of cancer. Low skeletal muscle mass is associated with poor clinical outcomes such as postoperative complications, chemotherapy toxicity and mortality in older cancer patients. Little is known about the mediating pathophysiological mechanisms. In this review we summarize proposed pathophysiological mechanisms underlying the association between low muscle mass and poor clinical outcomes in older cancer patients including 1) systemic inflammation; 2) insulin-dependent glucose handling; 3) mitochondrial function; 4) protein status, and; 5) pharmacokinetics of anticancer dr..

View full abstract


Awarded by European Union

Funding Acknowledgements

This work was supported by the European Union's Horizon 2020 research and innovation programme under the Marie-Sklodowska-Curie grant agreement no. 675003 (PANINI programme) and by an unrestricted grant of the University of Melbourne, Australia, received by Professor Andrea B. Maier. The funders had no role in the design and conduct of the study, data collection and analysis, interpretation of data, writing of the manuscript, or the decision to submit the article for publication.